Episode 1

23 min

Jul 12, 2026

‘PTCy – for ALL donors?’ w. Leo Luznik

‘PTCy – for ALL donors?’ w. Leo Luznik

In this episode Prof. Leo Luznik will describe how post-transplant cyclophosphamide as effective GvHD prophylaxis was detected and used after haploidentical allogeneic transplantation and its current and future role in HLA identical sibling, as well as in matched and mismatched unrelated stem cell transplantation.

CME Credits – 0.5 Credits

Guest

Prof. Leo Luznik

Leo Luznik is a Chief of Hematology and Oncology, Professor at the Department of Medicine and Physician in Chief, Dan L. Duncan CCC Baylor College of Medicine, Houston, USA. His primary research and clinical interests are in the area of allogeneic bone marrow transplantation. Besides conducting clinical trials, Leo Luznik is running an active laboratory research program, focused on the mechanisms of GvHD prevention with post-transplant cyclophosphamide and immunotherapy of acute leukemias.

More episodes

  • Episode 4

    29 min

    Oct 4, 2026

    ‘CAR T cells CURE and CAUSE cancer’ w. Roni Shouval

    In this episode, together with Roni Shouval, we discuss the evolution of CAR T cells and their potential for cure: what does cure actually mean? We will also touch the hot topic of their potential for causing cancer, how likely it is and what this means for patients and clinicians alike.

    Roni Shouval

  • Episode 3

    27 min

    Sep 6, 2026

    ‘Conditioning intensity MATTERS for allogeneic transplant’ w. C. Craddock

    In this episode Prof. Charles Craddock discusses the major aims of conditioning regimens prior to allogeneic stem cell transplantation and how to select proper intensity of the regimen to balance Graft versus Leukemia effect and regimen related toxicity.

    Prof. Charles Craddock

  • Episode 2

    26 min

    Aug 9, 2026

    ‘MPN - does spleen size REALLY matter?’ w. Claire Harrison

    In this episode, Prof. Claire Harrison discusses the central role of the spleen in myelofibrosis - from its biology and clinical significance to its dominance as trial endpoint. The conversation explores how spleen responses relate to symptoms, survival, disease heterogeneity, and the future of endpoint selection in MPN clinical trials.

    Prof. Claire Harrison

CME Accreditation

To receive your EBAH-CME accreditation points for this episode, please complete the following, selecting 1 correct answer for each question:

First name

Last name

Email address

EBAH member number

Question 1: Which of the following best describes the primary mechanism by which post-transplant cyclophosphamide (PTCy) prevents graft-versus-host disease (GvHD)?

Question 2: What is the current evidence regarding the impact of PTCy on graft-versus-leukemia (GvL) activity and relapse risk?

Question 3: Which statement best reflects the current clinical perspective on optimizing PTCy-based GvHD prophylaxis?